You are here

  • Home
  • Archive
  • Volume 9, Issue 6
  • Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial

Citation Tools

Article menu

This article has a correction. Please see:

XML
Clinical/translational cancer immunotherapy
Original research
Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Ferris RL, Spanos WC, Leidner R, et al
Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial
Journal for ImmunoTherapy of Cancer 2021;9:e002568. doi: 10.1136/jitc-2021-002568